X4 Pharmaceuticals

X4 Pharmaceuticals

Biotechnology
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

$289M

Market Cap • 11/16/2026

2010

(16 years)

Founded

2017

(9 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,1

P/S

17

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

5,1

BVPS

1,4

EPS

—

Market Cap

Market Cap

289M

EV

178,5M

EV/Revenue

10,5

EV/EBITDA

-2,3

EV/EBIT

-2,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-50,6%

Total Yield

-50,6%

Payout

0%

Retained Earnings

-651,1M

Profitability

Gross Margin

81,8%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

367,9%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0,1%

% Goodwill

7,5%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

1,8%

CAGR Net Income 5Y

0,9%

CAGR OCF 5Y

1,9%

Leverage

N.D./EBITDA

1,4

Debt/Equity

0%

Current Ratio

13,2

Quick Ratio

12,6

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium